Allergy vaccine - United Biomedical

Drug Profile

Allergy vaccine - United Biomedical

Alternative Names: Anti-IgE allergy vaccine - United Biomedical

Latest Information Update: 23 Sep 2016

Price : $50

At a glance

  • Originator United Biomedical
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypersensitivity
  • Preclinical Asthma

Most Recent Events

  • 23 Sep 2016 United Biomedical receives SBIR grant from the National Institute of Allergy and Infectious Diseases, for Allergy vaccine development in Hypersensitivity, before September 2016 (United Biomedical pipeline, September 2016)
  • 23 Sep 2016 Phase-I clinical trials in Hypersensitivity in USA (unspecified route), before September 2016 (United Biomedical pipeline, September 2016)
  • 30 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top